Cargando…

Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas

BACKGROUND: While the anti-PDGFRA antibody olaratumab failed to confirm an impact on survival in unselected advanced soft tissue sarcoma (STS) patients, the level of expression and the prognosis of platelet-derived growth factor (PDGF) receptors and ligands in STS remain unclear. PATIENTS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brahmi, M., Lesluyes, T., Dufresne, A., Toulmonde, M., Italiano, A., Mir, O., Le Cesne, A., Valentin, T., Chevreau, C., Bonvalot, S., Penel, N., Coindre, J.-M., Le Guellec, S., Le Loarer, F., Karanian, M., Blay, J.-Y., Chibon, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848659/ https://www.ncbi.nlm.nih.gov/pubmed/33524869 http://dx.doi.org/10.1016/j.esmoop.2020.100037

Ejemplares similares

Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma
por: Dufresne, A., et al.
Publicado: (2020)

French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak
por: Penel, N., et al.
Publicado: (2020)

Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma
por: Dantas-Barbosa, Carmela, et al.
Publicado: (2017)

Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)
por: Moreau-Bachelard, C., et al.
Publicado: (2022)

Surgery in reference centers improves survival of sarcoma patients: a nationwide study
por: Blay, J -Y, et al.
Publicado: (2019)

Surgery in reference centers improves survival of sarcoma patients: a nationwide study
por: Blay, J -Y, et al.
Publicado: (2019)

Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial
por: Filleron, Thomas, et al.
Publicado: (2020)

ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based case–control study—study protocol
por: Lacourt, Aude, et al.
Publicado: (2019)

Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study
por: Bompas, Emmanuelle, et al.
Publicado: (2018)

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group
por: Khalifa, J., et al.
Publicado: (2015)

Evolution of Patterns of Care and Outcomes in the Real-Life Setting for Patients with Metastatic GIST Treated in Three French Expert Centers over Three Decades
por: Toulmonde, Maud, et al.
Publicado: (2023)

ATRX Alteration Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas
por: Darmusey, Lucie, et al.
Publicado: (2021)

Clear Cell Sarcoma (Malignant Melanoma) of Soft Parts: A Clinicopathologic Study of 52 Cases
por: Hocar, O., et al.
Publicado: (2012)

P043 - Délais de prise en charge des sarcomes au sein des centres labellisés NETSARC+ pendant l’épidémie de COVID-19 et analyse des déterminants: étude COV-PEC-SARC
por: Cantarel, C., et al.
Publicado: (2023)

Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis
por: Debaudringhien, M., et al.
Publicado: (2022)

Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study
por: Savina, Marion, et al.
Publicado: (2017)

Tetraploidization of Immortalized Myoblasts Induced by Cell Fusion Drives Myogenic Sarcoma Development with DMD Deletion
por: Merle, Candice, et al.
Publicado: (2020)

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)(†)
por: Bompas, E., et al.
Publicado: (2015)

Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years
por: Basse, Clémence, et al.
Publicado: (2019)

Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin
por: Laroche, Audrey, et al.
Publicado: (2015)

Local and Metastatic Relapse Features in Patients After a Primary Soft Tissue Sarcoma: Advocating for a Better-Tailored Follow-Up
por: Blaye, Céline, et al.
Publicado: (2019)

Options thérapeutiques de prise en charge des sarcomes durant la pandémie COVID-19 : propositions du groupe sarcome français
por: Penel, Nicolas, et al.
Publicado: (2020)

Gene expression profiling improves prognostication by nomogram in patients with soft‐tissue sarcomas
por: Crombé, Amandine, et al.
Publicado: (2022)

Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials
por: Nassif, E.F., et al.
Publicado: (2022)

Impact of the coronavirus disease 2019 pandemic on sarcoma management in France: a 2019 and 2020 comparison
por: Penel, Nicolas, et al.
Publicado: (2023)

Patterns of care and outcome of CIC‐rearranged sarcoma patients: A nationwide study of the French sarcoma group
por: Brahmi, Mehdi, et al.
Publicado: (2022)

Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors
por: Dufresne, A., et al.
Publicado: (2023)

REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis
por: Berry, Vincent, et al.
Publicado: (2017)

PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic target
por: Bertucci, François, et al.
Publicado: (2019)

The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group
por: Perrier, Lionel, et al.
Publicado: (2018)

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma
por: Maillard, Maud, et al.
Publicado: (2020)

Medium levels of transcription and replication related chromosomal instability are associated with poor clinical outcome
por: Benhaddou, Ataaillah, et al.
Publicado: (2021)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms
por: Lesluyes, Tom, et al.
Publicado: (2017)

Analysis of the Peritumoral Tissue Unveils Cellular Changes Associated with a High Risk of Recurrence
por: Michot, Audrey, et al.
Publicado: (2023)

High frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management
por: Dômont, J, et al.
Publicado: (2010)

Determinants of the access to remote specialised services provided by national sarcoma reference centres
por: Fayet, Yohan, et al.
Publicado: (2021)

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
por: Toulmonde, Maud, et al.
Publicado: (2022)

Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study
por: Brodowicz, Thomas, et al.
Publicado: (2020)

TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials
por: Nassif, Elise F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cstae26bcoo9cnq2u14e74nqi8